Search research articles
Contact Us
Filters
Showing results (101-110 of 115) with videos related to
Page
of 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 11, 2021
Frequency and Prognostic Impact of <i>ALK</i> Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)
Angela Bellini, Ulrike Pötschger, Virginie Bernard, et al.
The Journal of Clinical Investigation
|
October 5, 2020
Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma
Evon Poon, Tong Liang, Yann Jamin, et al.
Nature Neuroscience
|
December 15, 2021
Retraction Note: Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma
Alexandra Garancher, Hiromichi Suzuki, Svasti Haricharan, et al.
Nature Chemical Biology
|
May 11, 2021
Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo
Christian Dubiella, Benika J Pinch, Kazuhiro Koikawa, et al.
Neuro-Oncology
|
February 7, 2026
MIF-CD74 signaling drives immune modulation in medulloblastoma
Benjamin Draper, Zhen You, Dean Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 12, 2025
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial
Juliet C Gray, Rebekah Weston, Cormac Owens, et al.
Nature Neuroscience
|
May 20, 2020
Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma
Alexandra Garancher, Hiromichi Suzuki, Svasti Haricharan, et al.
The Journal of Molecular Diagnostics : JMD
|
October 19, 2025
Harmonization of Reporting of ALK Genetic Alterations in Neuroblastoma: A SIOPEN Biology Study
Alexandra Saint-Charles, Julien Masliah-Planchon, Elnaz Saberi-Ansari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 8, 2024
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial
Lucas Moreno, Rebekah Weston, Cormac Owens, et al.
The Journal of Clinical Investigation
|
February 12, 2026
Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma
Lisa Werr, Jana Boland, Josephine Petersen, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 115) with videos related to
Sort By:
Page
of 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 11, 2021
Frequency and Prognostic Impact of <i>ALK</i> Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)
Angela Bellini, Ulrike Pötschger, Virginie Bernard, et al.
The Journal of Clinical Investigation
|
October 5, 2020
Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma
Evon Poon, Tong Liang, Yann Jamin, et al.
Nature Neuroscience
|
December 15, 2021
Retraction Note: Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma
Alexandra Garancher, Hiromichi Suzuki, Svasti Haricharan, et al.
Nature Chemical Biology
|
May 11, 2021
Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo
Christian Dubiella, Benika J Pinch, Kazuhiro Koikawa, et al.
Neuro-Oncology
|
February 7, 2026
MIF-CD74 signaling drives immune modulation in medulloblastoma
Benjamin Draper, Zhen You, Dean Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 12, 2025
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial
Juliet C Gray, Rebekah Weston, Cormac Owens, et al.
Nature Neuroscience
|
May 20, 2020
Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma
Alexandra Garancher, Hiromichi Suzuki, Svasti Haricharan, et al.
The Journal of Molecular Diagnostics : JMD
|
October 19, 2025
Harmonization of Reporting of ALK Genetic Alterations in Neuroblastoma: A SIOPEN Biology Study
Alexandra Saint-Charles, Julien Masliah-Planchon, Elnaz Saberi-Ansari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 8, 2024
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial
Lucas Moreno, Rebekah Weston, Cormac Owens, et al.
The Journal of Clinical Investigation
|
February 12, 2026
Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma
Lisa Werr, Jana Boland, Josephine Petersen, et al.
Page
of 12